The Biomedical Prevention Program has 41 investigators from 16 departments and four schools with a research base of $6.8 million in annual direct funding, Including $4.4 million from the NCI. Its members published 1092 papers over this grant period, of which 37% were intra-programmatic and 39% ware interprogrammatic collaborations. 155 of these publications were in high impact journals (Impact factor >7.51). The objective of the Biomedical Prevention Program is to reduce the morbidity and mortality caused by cancer through preventing the occurrence and improving survival with earlier diagnosis. The alms of the program are: 1) To build and to support organ-focused, vertically Integrated research projects that encompass environmental and genetic approaches In order to Identify individuals and populations a high risk for future neoplastic progression;2) To discover and validate biomarkers for risk assessment and early detection of common, high mortality cancers through the integration of high throughput genomic, proteomic, and biotechnologies;3) To Identify and determine preventive efficacy of Interventions with pharmacologic and nutritional tools with the aim of delaying or reversing neoplastic progression in individuals identified at high risk;and 4) To develop and validate new biostatistical methodologies to study population clusters and surrogate endpoints. The populations targeted for these programs include the general population and special at-risk groups.

Public Health Relevance

All of the research in the Biomedical Prevention Program has direct cancer relevance and covers the spectrum of research Including basic pharmacology of chemopreventive agents, gene discovery and risk modeling, proteomic studies that are directly applied to early detection, pharmacologic interventions Including Phase II, investigator initiated trials of chemopreventive agents, pharmacogenetic studies of preventive agents and outcomestudies including biomarkers, survival and prevention of treatment symptoms.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046592-25
Application #
8559868
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
25
Fiscal Year
2013
Total Cost
$240,152
Indirect Cost
$106,078
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Hoban, Connor W; Beesley, Lauren J; Bellile, Emily L et al. (2018) Individualized outcome prognostication for patients with laryngeal cancer. Cancer 124:706-716
Maust, Joel D; Frankowski-McGregor, Christy L; Bankhead 3rd, Armand et al. (2018) Cyclooxygenase-2 Influences Response to Cotargeting of MEK and CDK4/6 in a Subpopulation of Pancreatic Cancers. Mol Cancer Ther 17:2495-2506
Arthur, Anna E; Goss, Amy M; Demark-Wahnefried, Wendy et al. (2018) Higher carbohydrate intake is associated with increased risk of all-cause and disease-specific mortality in head and neck cancer patients: results from a prospective cohort study. Int J Cancer 143:1105-1113
Valenciaga, Anisley; Saji, Motoyasu; Yu, Lianbo et al. (2018) Transcriptional targeting of oncogene addiction in medullary thyroid cancer. JCI Insight 3:
Akkina, Sarah R; Kim, Roderick Y; Stucken, Chaz L et al. (2018) Is There a Difference in Staging and Treatment of Head and Neck Squamous Cell Tumors Between Tertiary Care and Community-Based Institutions? Laryngoscope Investig Otolaryngol 3:290-295
Anwar, Talha; Arellano-Garcia, Caroline; Ropa, James et al. (2018) p38-mediated phosphorylation at T367 induces EZH2 cytoplasmic localization to promote breast cancer metastasis. Nat Commun 9:2801
Giraldez, Maria D; Spengler, Ryan M; Etheridge, Alton et al. (2018) Comprehensive multi-center assessment of small RNA-seq methods for quantitative miRNA profiling. Nat Biotechnol 36:746-757
Hartlerode, Andrea J; Regal, Joshua A; Ferguson, David O (2018) Reversible mislocalization of a disease-associated MRE11 splice variant product. Sci Rep 8:10121
Fritsche, Lars G; Gruber, Stephen B; Wu, Zhenke et al. (2018) Association of Polygenic Risk Scores for Multiple Cancers in a Phenome-wide Study: Results from The Michigan Genomics Initiative. Am J Hum Genet 102:1048-1061
Haley, Henry R; Shen, Nathan; Qyli, Tonela et al. (2018) Enhanced Bone Metastases in Skeletally Immature Mice. Tomography 4:84-93

Showing the most recent 10 out of 1493 publications